Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN)
Kelowna, British Columbia – TheNewswire – April 21, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, has filed an important new patent application in the United States describing the use of its DehydraTECH™ technology for the delivery of antiviral drugs. The technology would potentially be used to improve treatment options for viral infectious diseases including COVID-19, MERS, SARS, influenza, herpes, hepatitis and AIDS.
This new patent application includes both method of use and composition of matter claims for the use of Lexaria’s DehydraTECH drug delivery technology as a means to increase the bioavailability and, we hypothesize, the effectiveness and tolerability of those oral, lipophilic antiviral drugs that otherwise demonstrate low gastrointestinal uptake and systemic delivery. This patent application also describes use of DehydraTECH to render dosage forms suitable for application to mucosal tissues of the oral, nasal, oropharyngeal, pulmonary and genitourinary tracts, as well as methods and compositions to combine antiviral drugs with anti-inflammatory drugs for enhanced therapeutic effectiveness.
“Lexaria’s proprietary drug delivery platform has already proven its effectiveness in the oral delivery of other lipophilic drugs such as nicotine, cannabinoids, and more, with multi-fold increases in both the rate and extent of bioabsorption,” said John Docherty, President of Lexaria Bioscience Corp. “We hypothesize that, once detailed testing begins, DehydraTECH will evidence improvements in the quantity and rapidity with which certain antiviral drugs are able to reach the human bloodstream after oral delivery. This has the potential to make a real contribution in the fight against COVID-19.”
Currently, many of the most effective antiviral drugs require administration by needle injection, an expensive delivery method that often requires refrigeration of the drug and administration by health care professionals. Although oral ingestible delivery (capsules, tablets, pills etc.) is much less expensive and less intrusive, many existing antiviral drugs delivered orally suffer from poor bioavailability and unpleasant side effects at doses high enough to be effective.
Lexaria believes that these drugs can be inexpensively processed with Lexaria’s DehydraTECH to improve the speed and extent with which they reach the bloodstream to, and in turn, improve their therapeutic potency, tolerability and cost-effectiveness, whether administered alone or in combination with anti-inflammatory agents that are often required to improve outcomes in virally infected patients.
According to the CDC, seasonal influenza affected 35.5 million Americans in 2018-2019 with 490,600 hospitalizations. If drugs such as rimantadine are administered soon after influenza infection prior to the cytokine storm inflammatory response taking effect, then many of the more serious disease consequences may be avoidable such as acute respiratory distress and pneumonia; which are also among the more dangerous symptoms of COVID-19. Lexaria’s newly submitted patent application specifically contemplates combination of anti-inflammatory drugs with antiviral drugs, all utilizing DehydraTECH, with a view to improved treatment outcomes for infectious disease states.
Lexaria will be filing for additional patent protection in many international markets, related to the use of DehydraTECH for delivery of antiviral drugs.
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way API’s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a federally licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
Sign up for MORE COVID-19 news updates
This article is written and published by The Stocks market
Disclaimer : The Stocks market does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Stocks market are engaged in the business of marketing and advertising companies.
The Stocks market and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.